Yi-Long Wu Selected Research

Therapeutics

1/2024	Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
1/2024	Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy.
12/2023	HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.
12/2023	HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
11/2023	Combination Therapy for EGFR-Mutated Lung Cancer.
11/2023	Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
10/2023	Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201).
10/2023	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
10/2023	Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.
7/2023	Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yi-Long Wu Research Topics

Disease

252	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 01/2005
128	Neoplasms (Cancer) 04/2024 - 09/2007
79	Lung Neoplasms (Lung Cancer) 11/2023 - 09/2007
37	Neoplasm Metastasis (Metastasis) 12/2023 - 07/2005
34	Disease Progression 04/2024 - 10/2009
26	Adenocarcinoma of Lung 01/2024 - 01/2012
18	Brain Neoplasms (Brain Tumor) 12/2023 - 07/2015
17	Diarrhea 04/2024 - 09/2009
16	Adenocarcinoma 01/2024 - 05/2007
14	Exanthema (Rash) 12/2023 - 11/2008
11	Neutropenia 04/2024 - 11/2008
10	Carcinoma (Carcinomatosis) 01/2023 - 01/2006
10	Nausea 01/2022 - 11/2011
9	Vomiting 01/2022 - 02/2014
8	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/2024 - 01/2016
6	Stomatitis 01/2023 - 02/2014
6	Fatigue 01/2018 - 10/2009
5	Acne Vulgaris 01/2018 - 11/2008
4	Anemia 04/2024 - 10/2018
4	Edema (Dropsy) 05/2023 - 12/2014
4	Vision Disorders (Hemeralopia) 10/2018 - 06/2013
4	Urinary Bladder Neoplasms (Bladder Cancer) 12/2015 - 03/2008
3	Leukopenia 04/2024 - 09/2010
3	Central Nervous System Diseases (CNS Diseases) 04/2024 - 10/2020
3	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2023 - 10/2009
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 09/2014
3	Pleural Effusion (Pleural Effusions) 01/2022 - 01/2020
3	Dermatitis 02/2021 - 11/2017
3	Paronychia 02/2021 - 02/2015
3	Alopecia (Baldness) 06/2013 - 11/2008
2	Acute Liver Failure (Fulminant Hepatic Failure) 12/2022 - 01/2022
2	Drug-Related Side Effects and Adverse Reactions 08/2022 - 05/2019
2	Pneumonia (Pneumonitis) 01/2022 - 11/2017
2	Sarcoma (Soft Tissue Sarcoma) 10/2021 - 07/2014

Drug/Important Bio-Agent (IBA)

108	ErbB Receptors (EGF Receptor)IBA 04/2024 - 01/2006
83	Tyrosine Kinase InhibitorsIBA 01/2024 - 09/2007
45	Gefitinib (Iressa)FDA Link 10/2023 - 05/2007
34	osimertinibIBA 03/2024 - 01/2017
32	PlatinumIBA 04/2024 - 11/2008
27	Biomarkers (Surrogate Marker)IBA 01/2024 - 09/2007
22	CrizotinibIBA 05/2023 - 06/2013
21	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 07/2013
20	Immune Checkpoint InhibitorsIBA 04/2024 - 01/2017
19	Pemetrexed (MTA)FDA Link 10/2023 - 10/2009
19	Carboplatin (JM8)FDA LinkGeneric 10/2023 - 01/2005
18	Anaplastic Lymphoma KinaseIBA 05/2023 - 03/2014
18	Proteins (Proteins, Gene)FDA Link 09/2022 - 06/2004
16	AfatinibIBA 04/2022 - 02/2014
14	B7-H1 AntigenIBA 01/2024 - 11/2018
14	Gemcitabine FDA Link 01/2023 - 03/2010
14	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2023 - 10/2009
13	Paclitaxel (Taxol)FDA LinkGeneric 10/2023 - 09/2009
11	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2009
10	Alanine Transaminase (SGPT)IBA 03/2021 - 08/2011
9	Messenger RNA (mRNA)IBA 01/2022 - 09/2007
8	Docetaxel (Taxotere)FDA Link 04/2024 - 11/2008
8	pembrolizumabIBA 12/2023 - 12/2017
8	Circulating Tumor DNAIBA 10/2023 - 12/2015
8	dacomitinibIBA 03/2021 - 11/2017
7	Phosphotransferases (Kinase)IBA 09/2022 - 09/2007
6	LigandsIBA 01/2022 - 04/2016
6	Aspartate Aminotransferases (Aspartate Transaminase)IBA 03/2021 - 11/2016
5	NivolumabIBA 01/2024 - 01/2019
5	RNA (Ribonucleic Acid)IBA 10/2023 - 01/2009
5	lorlatinibIBA 05/2023 - 08/2022
5	durvalumabIBA 01/2023 - 10/2020
5	MicroRNAs (MicroRNA)IBA 01/2022 - 03/2016
5	Bevacizumab (Avastin)FDA Link 01/2021 - 06/2012
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2023 - 01/2020
4	tislelizumabIBA 03/2023 - 01/2020
4	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2016
3	Irinotecan (Camptosar)FDA LinkGeneric 04/2024 - 09/2010
3	Carcinoembryonic AntigenIBA 01/2024 - 01/2009
3	camrelizumabIBA 07/2023 - 06/2022
3	AntibodiesIBA 01/2022 - 01/2021
3	icotinibIBA 12/2021 - 09/2013
3	ceritinibIBA 03/2021 - 01/2017
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 10/2009
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021 - 01/2018
3	Etoposide (VP 16)FDA LinkGeneric 10/2019 - 11/2016
3	VaccinesIBA 10/2011 - 06/2004
2	alectinibIBA 04/2024 - 01/2020
2	cyclo(Arg-Pro) (CI 4)IBA 05/2023 - 12/2015
2	Tumor Biomarkers (Tumor Markers)IBA 01/2023 - 01/2016
2	tepotinibIBA 01/2023 - 11/2020
2	Programmed Cell Death 1 ReceptorIBA 01/2023 - 01/2020
2	abivertinibIBA 01/2022 - 05/2019
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2021 - 07/2014
2	capmatinibIBA 04/2021 - 11/2018

Therapy/Procedure

89	Therapeutics 01/2024 - 05/2007
84	Drug Therapy (Chemotherapy) 04/2024 - 07/2005
29	Immunotherapy 04/2024 - 01/2009
9	Chemoradiotherapy 10/2023 - 08/2015
9	Neoadjuvant Therapy 01/2023 - 07/2005
7	Precision Medicine 01/2023 - 12/2009
6	Radiotherapy 10/2023 - 11/2011
6	Adjuvant Chemotherapy 07/2023 - 01/2017
3	Drug Tapering 01/2023 - 03/2021
3	Consolidation Chemotherapy 10/2019 - 08/2015
3	Lymph Node Excision (Lymph Node Dissection) 10/2017 - 08/2016